Overview

Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Status:
Active, not recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

BCD-089 is the original therapeutic monoclonal antibody binding the alpha subunit of the IL-6 receptor. The aim of the study is to demonstrate the efficacy and safety of BCD-089 in combination with methotrexate in patients with active rheumatoid arthritis resistant to monotherapy with methotrexate.

Phase:

Phase 3

Details

Lead Sponsor:

Biocad

Treatments:

Methotrexate